Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- elagolix
- Envarsus XR (tacrolimus)
Interactions between your drugs
tacrolimus elagolix
Applies to: Envarsus XR (tacrolimus), elagolix
MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.
MANAGEMENT: Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.
References (4)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Drug and food interactions
tacrolimus food
Applies to: Envarsus XR (tacrolimus)
ADJUST DOSING INTERVAL: Consumption of food has led to a 27% decrease in the bioavailability of orally administered tacrolimus.
MANAGEMENT: Tacrolimus should be administered at least one hour before or two hours after meals.
GENERALLY AVOID: Grapefruit juice has been reported to increase tacrolimus trough concentrations. Data are limited, but inhibition of the CYP450 enzyme system appears to be involved.
MANAGEMENT: The clinician may want to recommend that the patient avoid ingesting large amounts of grapefruit juice while taking tacrolimus.
References (2)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Eligard
Eligard (leuprolide) reduces levels of testosterone and is used to treat prostate cancer. Includes ...
Provera
Provera is used for abnormal uterine bleeding, amenorrhea, birth control, endometrial cancer ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Depo Provera
Depo-Provera is used as contraception to prevent pregnancy. It is also used to reduce pain cause by ...
Lupron Depot
Lupron Depot is used to treat advanced prostate cancer, endometriosis, uterine fibroids, and ...
Sprintec
Sprintec is used for abnormal uterine bleeding, birth control, endometriosis, gonadotropin ...
Zoladex
Zoladex (goserelin) is used to treat endometriosis and breast cancer in women and prostate cancer ...
Leuprolide
Leuprolide is used to treat endometriosis, prostate cancer, and early-onset puberty. Includes ...
Medroxyprogesterone
Medroxyprogesterone (Provera) treats conditions such as absent or irregular menstrual periods, or ...
Norethindrone
Norethindrone is used for abnormal uterine bleeding, amenorrhea, birth control, endometriosis ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.